S. McColley

发表

Polysomnography after adenotonsillectomy in mild pediatric obstructive sleep apnea.

G. Loughlin, M. Helfaer, S. McColley, 1996, Critical care medicine.

Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis.

S. McColley, M. Kwasny, M. Schechter, 2014, The Journal of pediatrics.

Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene

S. McColley, C. Powers, Manu Jain, 2016, Thorax.

Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities

G. Sawicki, S. McColley, M. Konstan, 2018, Journal of Clinical and Translational Science.

Finding the relevance of antimicrobial stewardship for cystic fibrosis.

L. Saiman, S. McColley, A. Holmes, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Combination lumacaftor and ivacaftor therapy for cystic fibrosis

S. McColley, 2016 .

Ivacaftor therapy for cystic fibrosis

S. McColley, 2014 .

Update in cystic fibrosis 2011.

S. McColley, F. Ratjen, 2012, American journal of respiratory and critical care medicine.

Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics.

E. Avner, H. Jacob, M. Hessner, 2019, Physiological genomics.

Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights

S. McColley, H. Levy, Xi Zhang, 2019, Genes.

Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature.

S. McColley, J. Costello, D. Steinhorn, 2002, Pediatrics.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

S. McColley, D. Waltz, E. Rietschel, 2014, The Lancet. Respiratory medicine.

Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function

Dave P. Miller, S. McColley, W. Morgan, 2007, Pediatrics.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

S. McColley, J. Elborn, R. Moss, 2015, The Lancet. Respiratory medicine.

Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population

S. McColley, R. Seshadri, C. Sullivan, 2009, Pediatric pulmonology.

Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis

S. McColley, C. Powers, R. Seshadri, 2004, Journal of Clinical Microbiology.

Practice guidelines, clinical trials, and unexpected results in cystic fibrosis.

S. McColley, 2014, Annals of the American Thoracic Society.

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

S. Peltz, S. McColley, E. Kerem, 2014, The Lancet. Respiratory medicine.

Longitudinal assessment of health‐related quality of life in an observational cohort of patients with cystic fibrosis

G. Sawicki, A. Quittner, S. McColley, 2011, Pediatric pulmonology.

Cystic fibrosis lung disease: when does it start, and how can it be prevented?

S. McColley, 2004, The Journal of pediatrics.

The demographics of adverse outcomes in cystic fibrosis

S. McColley, M. McGarry, Wadsworth A Williams, 2019, Pediatric pulmonology.

Update in pediatric lung disease 2012.

S. McColley, R. Morty, 2013, American journal of respiratory and critical care medicine.

Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

S. McColley, C. Powers, R. Seshadri, 2008, Translational research : the journal of laboratory and clinical medicine.

Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.

S. McColley, C. Owen, F. Ratjen, 2021, The Lancet. Respiratory medicine.

Cystic fibrosis year in review 2017

S. McColley, A. Savant, 2018, Pediatric pulmonology.

Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation.

S. Boas, S. McColley, S. Crawford, 2000, American journal of respiratory and critical care medicine.

Diagnosis of Cystic Fibrosis in Screened Populations

D. Sanders, M. Rosenfeld, H. Blau, 2017, The Journal of pediatrics.

ATS Consensus Statement: Research opportunities and challenges in pediatric pulmonology.

L. Lands, B. Wilfond, S. McColley, 2005, American journal of respiratory and critical care medicine.

Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections

S. McColley, A. Savant, 2020, Pediatric pulmonology.

Cystic fibrosis year in review 2016

S. McColley, A. Savant, 2017, Pediatric pulmonology.

Pediatric Cardiopulmonary Exercise Testing: Interoperability Through Domain Analysis Modeling and a National Survey

S. McColley, T. Keens, D. Cooper, 2022, Medicine and science in sports and exercise.

Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients.

S. McColley, K. Rychlik, A. Savant, 2020, Pediatric allergy, immunology, and pulmonology.

A randomized placebo-controlled trial of ataluren for the treatment of nonsense mutation cystic fibrosis

S. Peltz, S. McColley, F. Accurso, 2014 .

2014 year in review: Cystic fibrosis

S. McColley, A. Savant, Adrienne P. Savant, 2015, Pediatric pulmonology.

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.

G. Sawicki, S. McColley, C. Owen, 2019, The Lancet. Respiratory medicine.

Postexercise immune correlates in children with and without cystic fibrosis.

M. Danduran, S. Boas, S. McColley, 2000, Medicine and science in sports and exercise.

Parental Understanding of Newborn Screening for Cystic Fibrosis After a Negative Sweat-Test

L. Ross, S. McColley, L. Lester, 2011, Pediatrics.

Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID).

O. Sommerburg, S. McColley, C. Castellani, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition.

S. McColley, C. Castellani, P. Farrell, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening

D. Sanders, M. Rosenfeld, S. McColley, 2015, Pediatrics.

Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype

S. McColley, M. McGarry, 2021, Pediatric pulmonology.

Hispanic Infants with Cystic Fibrosis Show Low CFTR Mutation Detection Rates in the Illinois Newborn Screening Program

S. McColley, A. Harris, K. Watts, 2012, Journal of Genetic Counseling.

Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis

S. McColley, Manu Jain, T. Laguna, 2020, Pediatric pulmonology.

Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant.

S. McColley, R. Superina, E. Alonso, 2019, Journal of pediatric surgery.

Predicting the course of nutrition and lung disease in infants and children with cystic fibrosis.

S. McColley, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR

S. McColley, D. Waltz, E. Rietschel, 2017, Annals of the American Thoracic Society.

Cystic fibrosis year in review 2019: Section 1 CFTR modulators

S. McColley, A. Savant, 2020, Pediatric pulmonology.

Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States

S. McColley, P. Farrell, M. Sontag, 2022, International journal of neonatal screening.

Cystic fibrosis year in review 2018, part 1

S. McColley, A. Savant, 2019, Pediatric pulmonology.

Pediatric Pulmonology year in review 2015: Part 4

S. McColley, A. Savant, 2016, Pediatric pulmonology.

Cystic fibrosis year in review 2018, part 2

S. McColley, A. Savant, 2019, Pediatric pulmonology.

Sorting out the gray zone: Cystic fibrosis newborn screening.

S. McColley, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

M. Rosenfeld, S. McColley, M. Higgins, 2022, American journal of respiratory and critical care medicine.

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis

S. McColley, Maria Talamo Guevara, 2017, Expert opinion on drug safety.

In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies".

S. McColley, M. McGarry, J. Taylor-Cousar, 2022, Respiratory medicine.

Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening.

Lauren C. Balmert, S. McColley, K. Rychlik, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

S. McColley, B. Trapnell, M. Rolfe, 2012, American journal of respiratory and critical care medicine.

Immune response to influenza vaccination in children with renal disease

B. Fivush, S. McColley, S. Furth, 1995, Pediatric Nephrology.

Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients

S. McColley, K. Watts, 2011, Pediatric pulmonology.

Cystic fibrosis year in review 2019: Section 3 multisystem‐based care and research

S. McColley, A. Savant, 2020, Pediatric pulmonology.

Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course

S. McColley, A. Gordon, S. Khan, 2022, Journal of Clinical and Translational Science.

Trichosporon mycotoxinivorans Infection in Patients with Cystic Fibrosis

S. McColley, Xiaotian Zheng, D. Weil, 2014, Journal of Clinical Microbiology.

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

S. McColley, A. Hauser, M. Bar-Meir, 2011, Clinical Microbiology Reviews.

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

Margaret Rosenfeld, Frank Accurso, Philip M. Farrell, 2017, The Journal of pediatrics.

A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting.

S. McColley, Xiaotian Zheng, C. O'Malley, 2007, Respiratory care.

Lung function decline from adolescence to young adulthood in cystic fibrosis

Rory L. Michaelis, S. McColley, W. Morgan, 2012, Pediatric pulmonology.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Xiaohong Huang, Michael P Boyle, Carla Colombo, 2015, The New England journal of medicine.

Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis

S. McColley, Xi Zhang, H. Levy, 2019, Scientific Reports.

Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis

S. McColley, V. Legrys, M. Sontag, 2020, Pediatric Pulmonology.

Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review

S. McColley, Sheehan D. Fisher, J. Conviser, 2018, The International journal of eating disorders.

Pediatric Pulmonology

S. McColley, A. Savant, 2019 .

The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis.

S. McColley, P. Farrell, Zhanhai Li, 2010, The Journal of pediatrics.

Polysomnographic characteristics of patients with Rett syndrome.

C. Marcus, G. Loughlin, S. Naidu, 1994, The Journal of pediatrics.

Respiratory compromise after adenotonsillectomy in children with obstructive sleep apnea.

R. Naclerio, G. Loughlin, S. McColley, 1992, Archives of otolaryngology--head & neck surgery.

EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency.

K. Hardy, S. Boas, S. McColley, 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Airway microbiota across age and disease spectrum in cystic fibrosis

W. T. Harris, R. Gibson, J. Clancy, 2017, European Respiratory Journal.

Differences in expression of cystic fibrosis in blacks and whites.

S. McColley, G. Cutting, B. Rosenstein, 1991, American journal of diseases of children.

Immune Modulation Following Aerobic Exercise in Children with Cystic Fibrosis

M. Danduran, S. Boas, S. McColley, 2000, International journal of sports medicine.

Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management

Jeffrey B. Model, Tyler R. Ray, J. Rogers, 2021, Science Translational Medicine.

Inability of clinical history to distinguish primary snoring from obstructive sleep apnea syndrome in children.

C. Marcus, G. Loughlin, S. McColley, 1995, Chest.

High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea.

G. Loughlin, S. McColley, H. Sampson, 1997, Chest.

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

R. Gibson, S. McColley, D. Waltz, 2021, American journal of respiratory and critical care medicine.

A safety evaluation of ivacaftor for the treatment of cystic fibrosis

S. McColley, 2016, Expert opinion on drug safety.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

S. McColley, D. Waltz, B. Ramsey, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

S. McColley, M. Konstan, M. Schechter, 2009, The Journal of pediatrics.

Barriers to and solutions for representative inclusion across the lifespan and in life course research: The need for structural competency highlighted by the COVID-19 pandemic

P. Dayan, K. Bandeen-Roche, Y. Juhn, 2022, Journal of Clinical and Translational Science.

Energy metabolism during anaerobic exercise in children with cystic fibrosis and asthma.

M. Danduran, S. Boas, S. McColley, 1999, Medicine and science in sports and exercise.

Bronchopulmonary dysplasia. Impact of surfactant replacement therapy.

S. McColley, 1998, Pediatric clinics of North America.

Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study

S. McColley, M. Sontag, C. Ren, 2021, Pediatric pulmonology.

Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures

S. McColley, A. Savant, C. O'Malley, 2014, BMJ quality & safety.

Upper airway collapsibility in children with obstructive sleep apnea syndrome.

P. L. Smith, C. Marcus, G. Loughlin, 1994, Journal of applied physiology.

Update in pediatric lung disease 2011.

S. McColley, R. Morty, 2012, American journal of respiratory and critical care medicine.

Chapter 23 – Primary Snoring in Children

S. McColley, 2005 .

Cystic Fibrosis—Diagnosis, Genetics and Lifelong Effects

S. McColley, K. Boyne, 2021 .

Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.

S. McColley, M. McGarry, 2016, Annals of the American Thoracic Society.

Risk factors for mortality before age 18 years in cystic fibrosis

S. McColley, W. Morgan, M. Konstan, 2017, Pediatric pulmonology.

Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis

S. McColley, M. Konstan, D. Pasta, 2012, Pediatric pulmonology.

Refining the continuum of CFTR‐associated disorders in the era of newborn screening

S. McColley, P. Farrell, M. Nugent, 2016, Clinical genetics.

Designing trials for new cystic fibrosis modulators.

S. McColley, S. Cunningham, 2018, The Lancet. Respiratory medicine.

ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.

H. Tiddens, S. McColley, M. Skov, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

M. Rosenfeld, S. McColley, B. Ramsey, 2023, American journal of respiratory and critical care medicine.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

S. McColley, W. Morgan, M. Konstan, 2011, The Journal of pediatrics.

Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study

S. McColley, Joanne F. Cullina, H. Palac, 2017, BMC Pulmonary Medicine.

Wheezing or stridor: intrinsic and extrinsic lesions causing noisy breathing.

S. McColley, Peter H. Michelson, 1998, Allergy and Asthma Proceedings.

Disparities in Parental Health Literacy at a Pediatric Cystic Fibrosis Center.

S. McColley, K. Rychlik, K. Watts, 2015 .

Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis

S. McColley, Xi Zhang, H. Levy, 2019, Scientific Reports.

The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype.

A. Bharat, S. McColley, Joanne F. Cullina, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Barriers and facilitators to recruitment of underrepresented research participants: Perspectives of clinical research coordinators

R. D’Aquila, Marie E. Heffernan, M. Ison, 2023, Journal of Clinical and Translational Science.

Update in pediatric lung disease 2011.

S. McColley, R. Morty, 2012, American journal of respiratory and critical care medicine.

Obstructive Sleep Apnea Syndrome Clinical Practice Guideline : Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome

S. McColley, C. Chapman, S. Ward, 2002 .

Northwestern University Initiatives on Resource and Education Development for Collaborative AI in Learning Health System

David M. Liebovitz, Marianne M Green, M. Markl, 2022 .

Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients

S. McColley, K. Watts, 2011, Pediatric pulmonology.

Detection of disease‐causing CFTR variants in state newborn screening programs

S. McColley, P. Farrell, M. McGarry, 2022, Pediatric Pulmonology.

Late Diagnosis in the Era of Universal Newborn Screening Negatively Effects Short- and Long-Term Growth and Health Outcomes in Infants with Cystic Fibrosis.

S. McColley, P. Farrell, M. Sontag, 2023, The Journal of pediatrics.

Comment on Munck et al., Feb, 2021.

S. McColley, M. Sontag, C. Ren, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

S. McColley, D. Waltz, J. Davies, 2023, American journal of respiratory and critical care medicine.

Parental Attitudes About Exercise Regarding Their Children with Cystic Fibrosis

M. Danduran, S. Boas, S. McColley, 1999, International journal of sports medicine.